Propranolol monotherapy versus combined propranolol-gabapentin for prevention of paroxysmal sympathetic hyperactivity after moderate-severe traumatic brain injury: a randomized controlled trial Authors: Essamedin M Negm, Ahmed M Gouda, Mohammed El Mowafy Khatab, Essam Mohamed Elsayed Youssef, AnaSimon Alfred Foad Eskandr, Ola Mohammed Fathi, Heba Mohammed Fathi Published: 2026 ABSTRACT AbstractBackgroundParoxysmal sympathetic hyperactivity (PSH) is a serious complication of traumatic brain injury (TBI), characterized by episodic hypertension (HTN), tachycardia, hyperthermia, hyperhidrosis, and dystonia. It is associated with prolonged mechanical ventilation (MV), extended ICU and hospital stays, and worse outcomes. Current guidelines lack prophylactic recommendations.MethodologyThis single-center randomized controlled trial (NCT05427474) enrolled 90 adults with moderate-to-severe TBI glasgow coma scale (GCS 3–12). Participants were randomized to: standard care (Group I, n = 30); standard care plus propranolol (40 mg/12 h, Group II, n = 30); or standard care plus propranolol (40 mg/12 h) and gabapentin (100 mg/8 h, Group III, n = 30). The primary endpoint was PSH incidence. Secondary endpoints included ventilator days, ICU and hospital length of stay (LOS), and mortality.ResultsPSH incidence was lowest in Group III (10%) vs. Group II (33.3%) and Group I (60%) (p < 0.001). Group II showed the shortest MV duration (5.92 ± 5.15 days) vs. Group III (9.42 ± 6.99 days, p = 0.047) and Group I (12.92 ± 5.98 days, p < 0.001). ICU LOS was shortest in Group II (9.6 ± 5.32 days) vs. Group III (14.69 ± 8.35 days, p = 0.017) and Group I (19.5 ± 8.19 days, p < 0.001). Mortality and GCS improvement did not differ significantly (p > 0.05).ConclusionProphylactic propranolol significantly reduces PSH incidence, shortens MV duration, and decreases ICU stay in moderate-to-severe TBI. Although adding gabapentin further reduces PSH, it prolongs recovery time, suggesting a trade-off between efficacy and sedative effects. These findings suggest that propranolol monotherapy is a promising prophylactic strategy, with gabapentin potentially reserved for refractory cases. However, given the study's limitations, these results should be considered hypothesis-generating and warrant confirmation in larger, multicenter trials. Mortality and neurological outcomes were comparable across groups.Trial registrationThe trial was prospectively registered at ClinicalTrials.gov (NCT05427474) on June 22, 2022.Supplementary InformationThe online version contains supplementary material available at 10.1186/s12871-026-03802-2.Keywords: Traumatic Brain Injuries, Propranolol, Gabapentin, Paroxysmal Sympathetic Hyperactivity, Autonomic Nervous System Diseases, Secondary Prevention, Adrenergic beta-Antagonists, Critical Care Outcomes, Length of Stay, Randomized Controlled Trial Introduction Paroxysmal sympathetic hyperactivity (PSH) is a serious and frequently overlooked complication of traumatic brain injury (TBI), with its highest incidence observed in the neurocritical care population following moderate-to-severe TBI, where it is reported to affect between 8% and 33% of individuals, and up to 50% in cohorts with the most severe injuries [1–3]. It presents as recurrent surges of sympathetic activity manifesting with hypertension (HTN), tachycardia, hyperthermia, hyperhidrosis, and dystonia driven by excessive catecholamine release [4]. Beyond its distressing clinical features, PSH is an independent predictor of prolonged mechanical ventilation (MV), extended intensive care unit (ICU) and hospital stays, and substantial increases in healthcare costs [5]. Crucially, each episode can aggravate secondary brain injury through hypermetabolism, excitotoxic neuronal damage, and elevated intracranial pressure (ICP) [2], thereby fueling a broader injury cascade linked to poor outcomes in severe TBI [6]. Despite this significant clinical and economic burden, PSH prevention remains absent from current TBI management guidelines [7]. Present-day strategies are almost exclusively reactive, aiming to control symptoms after onset and often relying on anecdotal or low-quality evidence. International consensus recognizes β-blockers, such as propranolol, and gamma-aminobutyric acid (GABA) analogs, such as gabapentin, as first-line agents for PSH management [8]. However, two fundamental questions remain unanswered: first, can early administration of these agents prevent the development of PSH? Second, does combining a peripheral β-adrenergic blocker with a central GABAergic modulator offer a synergistic advantage over monotherapy [8]? The biological rationale for such a dual prophylactic approach is compelling. Propranolol counteracts peripheral catecholamine toxicity and reduces cerebral hyperemia, while gabapentin dampens excitatory neurotransmission in thalamocortical circuits implicated in PSH pathogenesis [9]. Together, they may interrupt the autonomic dysregulation that triggers sympathetic storms. Yet, the sedative potential of gabapentin raises concerns about slower recovery trajectories highlighting a possible trade-off between maximal PSH prevention and rehabilitation speed [10]. To address these uncertainties, we conducted a randomized controlled trial designed to evaluate whether early prophylaxis with propranolol–gabapentin reduces PSH incidence compared with propranolol monotherapy or standard care. The study also assessed the impact of these interventions on recovery kinetics, measured by MV duration and ICU and hospital length of stay (LOS), as well as safety outcomes including mortality and neurological status. Patients and methods Study design and setting This prospective randomized controlled trial was conducted in the ICU at Zagazig University Hospitals over an 11-month period, from December 1, 2022, to October 31, 2023. The study was designed and reported in accordance with the Consolidated Standards of Reporting Trials (CONSORT) guidelines. A total of 90 patients with moderate-to-severe TBI admitted to the ICU during this period were enrolled. Ethical approval The study protocol was approved by the Institutional Review Board (IRB) of the Faculty of Medicine, Zagazig University (IRB No. 9076/8-11-2021). Written informed consent was obtained from the first-degree relatives of all participants after a detailed explanation of the study. Inclusion criteria Patients were eligible if they were admitted to the ICU with moderate to severe TBI, defined by Glasgow Coma Scale (GCS) score of 9–12 for moderate cases and 3–8 for severe cases [11]. Additional eligibility requirements included an age between 18 and 64 years, both male and female patients, and the availability of a first-degree relative able to provide written informed consent. Exclusion criteria Patients were excluded if they had pre-existing brain dysfunction, allergy to propranolol or gabapentin, significant cardiac disease, chronic kidney disease, cervical spine injury, or chronic obstructive pulmonary disease (COPD). Patients presenting with bradycardia, uncontrolled HTN, or hypotension upon ICU admission were also excluded. Those receiving active propranolol or gabapentin therapy at screening were excluded. Sample size calculation The sample size was calculated a priori based on the primary outcome (PSH incidence). Assuming a control incidence of 50% and a reduction to 30% with active prophylaxis, with α = 0.05 and 80% power, the required sample size was 81 patients. To account for potential dropouts, the sample size was increased to 90 patients (30 per group). The calculation was performed using G*Power software (version 3.1.9.4). Method of randomization After obtaining informed consent, patients were randomly allocated in a 1:1:1 ratio into three groups using a computer-generated sequence prepared by an independent investigator. Allocation was concealed using sequentially numbered, sealed, opaque envelopes opened after enrollment. Blinding of the study The study medications (propranolol, gabapentin, and their respective placebos) were prepared in identical capsules and packaged in neutral, coded containers by a pharmacist not involved in patient care or data analysis. Standard care was provided uniformly across all groups, with placebo capsules administered at the same schedule as the active drugs to maintain treatment masking. Treating ICU physicians were aware of group allocation due to the need for dose adjustment and safety monitoring, but they did not participate in outcome assessments. The clinical team responsible for diagnosing PSH, recording ventilator duration, ICU/hospital LOS, and compiling outcome data was blinded to group assignments. Importantly, this clinical endpoint adjudication team was responsible for diagnosing PSH strictly according to the international consensus criteria [12] and operated independently from the treating physicians. Data analysts were also blinded until after the completion of statistical analysis. Study groups Patients were randomized into three groups (1:1:1): Control (standard TBI care), Propranolol (standard care plus propranolol), and Combination (standard care plus propranolol and gabapentin), administered orally or via nasogastric tube (PO/NGT). Drug dosing and mechanisms are detailed in Supplementary Table 1. Treatment continued until discharge or death, and all other ICU care followed institutional TBI protocols. Baseline assessment Upon ICU admission, all patients underwent a comprehensive baseline evaluation, including detailed medical history (age, sex, comorbidities, surgical history, current medications, and final diagnosis), full clinical examination, and routine laboratory investigations. Primary and secondary trauma surveys were performed for all patients. A small number of patients had a remote history of gabapentin use that had been discontinued prior to admission; these patients were not on active therapy at the time of injury and were managed per protocol as gabapentin-naïve. Interventions All patients received standard TBI management according to the institutional ICU protocol [13]. This included ICP monitoring in patients with GCS ≤ 8, maintenance of mean arterial pressure (MAP) above 80 mmHg, MV for patients with PaO₂/FiO₂ < 300, and initiation of enteral nutrition within 48 h of admission. For Groups II and III, trial medications were initiated within 6 h of ICU admission and continued until hospital discharge or death. Group II received propranolol only, while Group III received both propranolol and gabapentin. The dosing regimens were propranolol 40 mg every 12 h and gabapentin 100 mg every 8 h. These doses were selected based on previously published clinical series and with a primary focus on safety for prophylactic use in critically ill patients. Study flow The sequence of data presentation in the Results section was predefined to follow the clinical trajectory of patients. Study flow included: baseline characteristics → trauma severity → initial clinical and radiological assessment → ICU admission and follow-up → primary outcome (PSH incidence and profile) → ICU complications and management → duration of MV and ICU stay → discharge status → neurological recovery. Study outcomes Primary outcome The primary outcome was PSH incidence, diagnosed according to international consensus criteria [12]. Episodes were defined by the presence of at least three simultaneous features per day: tachycardia (heart rate (HR) > 120 bpm), HTN (systolic blood pressure (SBP) > 140 mmHg), tachypnea (respiratory rate (RR) > 30 breaths/min), diaphoresis, with or without dystonia or hyperthermia (> 38.5 °C), in the absence of other causes. Secondary outcomes Secondary outcomes were selected to measure the potential clinical and resource utilization benefits stemming from the prevention of PSH. These included: (1) duration of MV, as PSH episodes directly impede weaning; (2) ICU and hospital LOS, as PSH prolongs acute care; (3) all-cause mortality; (4) change in GCS score from admission to discharge, as a measure of neurological recovery; and (5) ICU complications. Infectious complications (e.g., pneumonia, sepsis) were identified and monitored from ICU admission until hospital discharge using standard clinical and microbiological criteria as part of the safety assessment. Statistical analysis Data were analyzed using IBM SPSS Statistics (version 23.0). Continuous variables are presented as mean ± standard deviation (SD), and categorical variables as frequencies and percentages (n, %). The primary outcome (PSH incidence) was compared across groups using the Chi-square test, with pairwise comparisons using Bonferroni correction. Results are reported as counts (%) with relative risk and 95% confidence intervals (CIs). For secondary continuous outcomes (MV duration, ICU LOS, hospital LOS), between-group comparisons were performed using one-way analysis of variance (ANOVA). Post-hoc pairwise comparisons were conducted using Tukey’s Honestly Significant Difference (HSD) test. When ANOVA assumptions were violated, the non-parametric Kruskal-Wallis H test was employed, followed by Dunn’s test with Bonferroni adjustment. Within-group changes in GCS were analyzed using paired t-test. A post-hoc descriptive analysis of daily HR and SBP was performed over 14 days, with results presented as median and interquartile range (IQR). All analyses were conducted on an intention-to-treat (ITT) basis. Durations for patients who died were censored at death. Treatment administration was monitored via electronic records; adherence was high (~ 92% of doses administered), with minor deviations due to transient clinical circumstances. A two-tailed p-value < 0.05 was considered statistically significant. Results Study population and baseline characteristics Of 142 patients assessed for eligibility, 52 were excluded (26 declined, 26 met exclusion criteria). Ninety patients were randomized equally into three groups (n = 30 each) and completed the study with no loss to follow-up (Fig. 1). The three groups were well matched for demographic, clinical, and injury characteristics, with no statistically significant differences (Table 1). Age, sex, body mass index (BMI), comorbidities including HTN, diabetes mellitus (DM), and hepatitis C virus (HCV) infection, and medication history were comparable across groups. Trauma mechanism and TBI severity were similar across groups. Road traffic accidents (RTA) accounted for > 90% of injuries, and severe TBI predominated (60–63%) (Table 2). Baseline computed tomography (CT) findings were comparable, with tense cerebral edema as the most common finding (53–57%). Extracranial injuries and laboratory parameters showed no significant intergroup differences (Table 3). Consort flow diagram of patient population through each stage of the randomized trial Table 1Demographic, medical, surgical, and medication history of the three studied groupsVariableGroup I (n = 30)Group II (n = 30)Group III (n = 30)Test valueP valueSig.Age (years)31.03 ± 10.9732.27 ± 12.2031.40 ± 11.280.0910.913NSRange18–6418–6218–60Gender0.9340.627NSMale24 (80.0%)22 (73.3%)25 (83.3%)Female6 (20.0%)8 (26.7%)5 (16.7%)BMI (kg/m²)24.07 ± 4.5324.03 ± 4.1423.63 ± 3.320.1090.897NSRange18.5–33.518.5–30.318.9–30.2Past medical & surgical history0.2710.873NSAbsent18 (60.0%)16 (53.3%)17 (56.7%)Present12 (40.0%)14 (46.7%)13 (43.3%)Smoking0.1170.943NSNon-smoker23 (76.7%)22 (73.3%)22 (73.3%)Current smoker7 (23.3%)8 (26.7%)8 (26.7%)ComorbiditiesDM4 (13.3%)4 (13.3%)4 (13.3%)0.00.999NSHTN4 (13.3%)5 (16.7%)5 (16.7%)0.1690.919NSHCV0 (0.0%)4 (13.3%)1 (3.3%)5.5060.064NSPrevious surgeriesThyroidectomy1 (3.3%)0 (0.0%)0 (0.0%)2.0220.364NSAppendectomy1 (3.3%)1 (3.3%)3 (10.0%)1.6940.429NSCholecystectomy0 (0.0%)1 (3.3%)0 (0.0%)2.0220.364NSPast medication history0.00.999NSPresent9 (30.0%)9 (30.0%)9 (30.0%)L-thyroxin1 (3.3%)0 (0.0%)0 (0.0%)2.0220.364NSInsulin0 (0.0%)2 (6.7%)1 (3.3%)2.0690.355NSOHD4 (13.3%)2 (6.7%)3 (10.0%)0.7410.690NSAnti-HTN4 (13.3%)5 (16.7%)5 (16.7%)0.1690.919NSData are presented as mean ± SD or number (%). NS Non-significant (p > 0.05), BMI Body Mass Index, HTN Hypertension, DM Diabetes Mellitus, HCV Hepatitis C Virus, OHD Oral hypoglycemic drugs, Anti-HTN Antihypertensive drugs Demographic, medical, surgical, and medication history of the three studied groups Data are presented as mean ± SD or number (%). NS Non-significant (p > 0.05), BMI Body Mass Index, HTN Hypertension, DM Diabetes Mellitus, HCV Hepatitis C Virus, OHD Oral hypoglycemic drugs, Anti-HTN Antihypertensive drugs Table 2Comparison between the three groups studied regarding type of trauma and level of TBIVariable Group I (n = 30) Group II (n = 30) Group III (n = 30) Test valuep-valueSig.Type of traumaDirect trauma0 (0.0%)1 (3.3%)2 (6.7%)2.5960.627NSFFH1 (3.3%)2 (6.7%)1 (3.3%)RTA29 (96.7%)27 (90.0%)27 (90.0%)Level of TBIModerate11 (36.7%)11 (36.7%)12 (40.0%)0.0950.954NSSevere19 (63.3%)19 (63.3%)18 (60.0%)Data are presented as number (%). NS Non-significant (p > 0.05), FFH Falling from height, RTA Road traffic accident, TBI Traumatic brain injury Comparison between the three groups studied regarding type of trauma and level of TBI Data are presented as number (%). NS Non-significant (p > 0.05), FFH Falling from height, RTA Road traffic accident, TBI Traumatic brain injury Table 3Comparison between the three groups studied regarding radiological, clinical, and laboratory characteristics at admissionParameterGroup I (n = 30)Group II (n = 30)Group III (n = 30)Test valueP valueSig.CT BrainTense cerebral edema16 (53.3%)17 (56.7%)16 (53.3%)0.0900.956NSBrain contusion6 (20.0%)6 (20.0%)7 (23.3%)0.1330.935NSIntracranial hemorrhage6 (20.0%)8 (26.7%)9 (30.0%)0.8180.664NSSAH10 (33.3%)8 (26.7%)6 (20.0%)1.3640.506NSEDH1 (3.3%)2 (6.7%)3 (10.0%)1.0710.585NSSDH6 (20.0%)1 (3.3%)5 (16.7%)4.0380.133NSDAI0 (0%)1 (3.3%)0 (0%)2.0220.364NSCT Chest/PAUS/OrthopedicLung contusion10 (33.3%)13 (43.3%)11 (36.7%)0.6620.718NSRib fracture0 (0%)0 (0%)1 (3.3%)2.0220.364NSThoracic spine injury0 (0%)1 (3.3%)0 (0%)2.0220.364NSLumbar spine injury1 (3.3%)0 (0%)0 (0%)2.0220.364NSSplenic injury1 (3.3%)1 (3.3%)1 (3.3%)0.0001.000NSHepatic injury1 (3.3%)0 (0%)1 (3.3%)1.0230.600NSPelvic fracture1 (3.3%)2 (6.7%)1 (3.3%)0.5230.770NSClinical dataGCS (Mean ± SD)7.90 ± 2.768.07 ± 2.418.03 ± 2.300.0370.963NSHR (Mean ± SD)92.93 ± 8.9091.27 ± 10.2492.67 ± 9.000.2720.762NSSBP (Mean ± SD)119.67 ± 11.44120.67 ± 9.17122.17 ± 8.680.4910.614NSDBP (Mean ± SD)75.33 ± 8.6075.67 ± 9.7177.00 ± 6.510.3320.718NSO₂ saturation (%)96.13 ± 1.8095.33 ± 2.1595.40 ± 2.211.3920.254NSHb (g/dl)12.73 ± 1.5612.59 ± 1.7712.54 ± 1.150.1350.874NSPTT (sec)28.47 ± 3.0129.70 ± 3.5129.57 ± 3.791.1530.320NSINR1.08 ± 0.081.07 ± 0.081.07 ± 0.100.0850.919NSCharacteristic labsLeukocytosis4 (13.3%)6 (20.0%)5 (16.7%)0.4800.787NSCRP increased4 (13.3%)6 (20.0%)5 (16.7%)0.4800.787NSLiver enzymes ↑3 (10.0%)2 (6.7%)2 (6.7%)0.3100.856NSSputum culture +ve4 (13.3%)4 (13.3%)4 (13.3%)0.0001.000NSBlood culture +ve0 (0%)2 (6.7%)0 (0%)4.0910.129NSUrine culture +ve0 (0%)1 (3.3%)0 (0%)2.0220.364NSCVL culture +ve0 (0%)2 (6.7%)2 (6.7%)2.0930.351NSData are presented as mean ± SD or number (%). NS Non-significant (p > 0.05), GCS Glasgow Coma Scale, HR Heart rate, SBP Systolic blood pressure, DBP Diastolic blood pressure, Hb Hemoglobin, PAUS Pelvic-abdominal ultrasound, PTT Partial thromboplastin time, INR International normalized ratio, CRP C-reactive protein, SAH Subarachnoid hemorrhage, EDH Epidural hematoma, SDH Subdural hemorrhage, DAI Diffuse axonal injury, CVL Central venous line Comparison between the three groups studied regarding radiological, clinical, and laboratory characteristics at admission Data are presented as mean ± SD or number (%). NS Non-significant (p > 0.05), GCS Glasgow Coma Scale, HR Heart rate, SBP Systolic blood pressure, DBP Diastolic blood pressure, Hb Hemoglobin, PAUS Pelvic-abdominal ultrasound, PTT Partial thromboplastin time, INR International normalized ratio, CRP C-reactive protein, SAH Subarachnoid hemorrhage, EDH Epidural hematoma, SDH Subdural hemorrhage, DAI Diffuse axonal injury, CVL Central venous line All patients were admitted for management of moderate-to-severe TBI. Secondary admission triggers (e.g., disturbed consciousness, pneumonia, respiratory distress (RD)) occurred sporadically with no systematic group distribution (all *p* > 0.05) (Table 4). On follow-up imaging, persistent brain edema was significantly less frequent in the treatment groups, particularly Group III (3.3% vs. 26.7% in controls, *p* = 0.020). Other radiological findings did not differ significantly. Table 4Comparison between the three studied groups regarding causes of ICU admission and follow-up radiological/clinical findings.=VariableGroup I (n = 30)Group II (n = 30)Group III (n = 30)Test value*p-valueSig.Cause of ICU admissionDCL2 (6.7%)2 (6.7%)1 (3.3%)0.4240.809NSPneumonia1 (3.3%)1 (3.3%)1 (3.3%)0.0001.000NSRD0 (0%)0 (0%)2 (6.7%)4.0910.129NSLung collapse1 (3.3%)0 (0%)1 (3.3%)1.0230.600NSPneumothorax1 (3.3%)0 (0%)1 (3.3%)1.0230.600NSFits1 (3.3%)1 (3.3%)2 (6.7%)0.5230.770NSHematemesis0 (0%)1 (3.3%)0 (0%)2.0220.364NSPostoperative1 (3.3%)2 (6.7%)2 (6.7%)0.4240.809NSFollow-up CT brainBrain edema (resolving / mild / moderate / tense)11 / 2 / 9 / 810 / 3 / 11 / 68 / 11 / 10 / 115.0080.020SBrain contusion (absent / resolving / present)25 / 1 / 425 / 1 / 426 / 1 / 30.2080.995NSEpidural rim (absent / present)29 / 130 / 028 / 22.0690.355NSIntracranial hematoma (absent / resolving / present)24 / 2 / 422 / 1 / 721 / 4 / 53.0840.544NSSAH (absent / resolving / present)20 / 4 / 622 / 6 / 223 / 5 / 23.8150.432NSSDH (absent / present)26 / 428 / 225 / 51.4500.484NSEDH (absent / resolving / present)29 / 0 / 128 / 2 / 027 / 3 / 04.8710.301NSDAI (absent / present)27 / 328 / 228 / 20.3100.856NSSkull fracture (absent / depressed / fissure / base)25 / 4 / 0 / 124 / 3 / 2 / 125 / 4 / 1 / 03.2090.782NSFollow-up chest & abdominalLung contusion (absent / resolving / present)21 / 3 / 622 / 1 / 727 / 0 / 36.0110.198NSIntraperitoneal free fluid (absent / minimal)28 / 226 / 428 / 21.0980.578NSSpleen (absent / injury / splenectomy)29 / 1 / 029 / 0 / 129 / 1 / 03.0000.558NSHepatic injury (absent / present)29 / 130 / 028 / 22.0690.355NSRib fracture (absent / present)30 / 030 / 029 / 12.0220.364NSOperation (absent / cranial / non-cranial / both)17 / 10 / 3 / 019 / 7 / 3 / 114 / 15 / 1 / 06.9650.324NSData are presented as number (%). NS Non-significant (p > 0.05), S Significant (p < 0.05), DCL Disturbed conscious level, RD Respiratory distress, CT Computed tomography, PAUS Pelvic-abdominal ultrasound, SAH Subarachnoid hemorrhage, SDH Subdural hemorrhage, EDH Epidural hematoma, DAI Diffuse axonal injury, ICU Intensive care unit Comparison between the three studied groups regarding causes of ICU admission and follow-up radiological/clinical findings.= Data are presented as number (%). NS Non-significant (p > 0.05), S Significant (p < 0.05), DCL Disturbed conscious level, RD Respiratory distress, CT Computed tomography, PAUS Pelvic-abdominal ultrasound, SAH Subarachnoid hemorrhage, SDH Subdural hemorrhage, EDH Epidural hematoma, DAI Diffuse axonal injury, ICU Intensive care unit Primary outcome: PSH incidence and symptom profile PSH incidence differed significantly across groups (*p* < 0.001). It occurred in 60% of Group I (control), 33.3% of Group II (propranolol), and 10% of Group III (combination). Pairwise comparisons were all significant (Table 5). Table 5Comparison between the three studied groups regarding PSH incidencePSHGroup I (n = 30)Group II (n = 30)Group III (n = 30)Test value*p-valueSig.Absent12 (40.0%)20 (66.7%)27 (90.0%)16.6320.000HSPresent18 (60.0%)10 (33.3%)3 (10.0%) Post Hoc analysis Group I Vs Group II Group I Vs Group III Group II Vs Group III 0.0380.0000.028Data are presented as number (percentage). Test value*: Chi-square test was used. Post hoc analysis was performed to detect intergroup differences. p < 0.05 is considered significant (S); p < 0.01 is considered highly significant (HS); NS not significant. PSH Paroxysmal Sympathetic Hyperactivity Comparison between the three studied groups regarding PSH incidence Data are presented as number (percentage). Test value*: Chi-square test was used. Post hoc analysis was performed to detect intergroup differences. p < 0.05 is considered significant (S); p < 0.01 is considered highly significant (HS); NS not significant. PSH Paroxysmal Sympathetic Hyperactivity Mean time to PSH onset was similar across groups (7.3–9.1 days, *p* = 0.082). Regarding symptom distribution, significant intergroup differences were observed for tachycardia (*p* = 0.012), HTN (*p* = 0.002), and sweating (*p* = 0.012), with the lowest rates in Group II and Group III (Table 6). Tachypnea, posturing, and hyperthermia did not differ significantly. Use of rescue medications mirrored PSH incidence (60% in Group I, 33.3% in Group II, 10% in Group III). Both treatment groups showed sustained attenuation of daily HR and SBP compared to controls, with Group III exhibiting the most stable reduction (Supplementary Table 6). Table 6Comparison between the three studied groups regarding PSH onset and symptomsParameter Group I (n> = 30) Group II (n = 30) Group III (n = 30) Test value*p-valueSig. Overall (n = 31*) Onset of PSH (days)7.27 ± 3.06 (1–14)8.03 ± 2.97 (1–14)9.1 ± 3.34 (2–14)2.5680.082NS—Tachypnea9 (50.0%)2 (20.0%)1 (33.3%)2.4790.290NS12 (38.7%)Tachycardia14 (77.8%)2 (20.0%)2 (66.7%)8.9140.012S18 (58.1%)HTN14 (77.8%)1 (10.0%)1 (33.3%)12.2690.002HS16 (51.6%)Sweating14 (77.8%)2 (20.0%)2 (66.7%)8.9140.012S18 (58.1%)Posturing6 (33.3%)1 (10.0%)0 (0.0%)2.9710.226NS7 (22.6%)Hyperthermia9 (50.0%)3 (30.0%)1 (33.3%)1.1570.561NS13 (41.9%)Data are presented as mean ± SD (range) or number (percentage). ANOVA test was used for continuous variables and Chi-square test for categorical variables. p < 0.05 is considered significant (S); p < 0.01 highly significant (HS); NS not significant. PSH Paroxysmal Sympathetic Hyperactivity*Overall descriptive data (n = 31 patients with PSH) are presented for symptoms Comparison between the three studied groups regarding PSH onset and symptoms Data are presented as mean ± SD (range) or number (percentage). ANOVA test was used for continuous variables and Chi-square test for categorical variables. p < 0.05 is considered significant (S); p < 0.01 highly significant (HS); NS not significant. PSH Paroxysmal Sympathetic Hyperactivity *Overall descriptive data (n = 31 patients with PSH) are presented for symptoms Secondary outcomes Overall complication rates were similar across groups (26.7%, 30%, and 16.7% in Groups I–III, respectively; *p* > 0.05). Pneumonia, ventilator-associated pneumonia (VAP), sepsis, and drug-induced hepatitis occurred at comparable frequencies. Hypotensive episodes were infrequent and predominantly sepsis-related, with no excess risk in propranolol-containing groups (Supplementary Table 2). MV requirement and sedation practices did not differ significantly across groups (Supplementary Table 3). Significant intergroup differences were observed for MV duration, ICU stay, and hospital LOS (*p* < 0.01). Group II (propranolol) had the shortest MV duration (5.9 ± 5.2 days), ICU stay (9.6 ± 5.3 days), and hospital LOS (11.9 ± 6.1 days), followed by Group III, with Group I having the longest durations (all *p* < 0.05) (Table 7). Table 7Comparison between the three studied groups regarding Mechanical ventilation duration, ICU length of stay, and hospital length of stay (days)Parameter Group I (n = 30) Group II (n = 30) Group III (n = 30) Test valueP-valueSig.Post Hoc (LSD)MV duration (days)12.92 ± 5.98 (1–23)5.92 ± 5.15 (1–25)9.42 ± 6.99 (1–37)7.8650.001HSI vs. II: 0.000**I vs. III: 0.047*II vs. III: 0.047*ICU stay (days)19.50 ± 8.19 (6–39)9.60 ± 5.32 (2–25)14.69 ± 8.35 (1–37)10.910< 0.001HSI vs. II: 0.000**I vs. III: 0.025*II vs. III: 0.017*Hospital stay (days)21.57 ± 9.93 (6–39)11.87 ± 6.08 (3–27)17.03 ± 8.59 (5–37)10.126< 0.001HSI vs. II: 0.000**I vs. III: 0.038*II vs. III: 0.019*Data are presented as mean ± SD (range). These analyses include all randomized patients on an intention-to-treat basis, with durations for deceased patients censored at the time of death. Mortality rates by group are provided in Supplementary Table 4LSD least significant difference, NS Non-significant (p > 0.05), S Significant (p < 0.05), HS Highly significant (p < 0.01). * p < 0.05, ** p < 0.01 (Post Hoc LSD test). MV Mechanical ventilation, ICU Intensive care unit Comparison between the three studied groups regarding Mechanical ventilation duration, ICU length of stay, and hospital length of stay (days) I vs. II: 0.000** I vs. III: 0.047* II vs. III: 0.047* I vs. II: 0.000** I vs. III: 0.025* II vs. III: 0.017* I vs. II: 0.000** I vs. III: 0.038* II vs. III: 0.019* Data are presented as mean ± SD (range). These analyses include all randomized patients on an intention-to-treat basis, with durations for deceased patients censored at the time of death. Mortality rates by group are provided in Supplementary Table 4 LSD least significant difference, NS Non-significant (p > 0.05), S Significant (p < 0.05), HS Highly significant (p < 0.01). * p < 0.05, ** p < 0.01 (Post Hoc LSD test). MV Mechanical ventilation, ICU Intensive care unit Discharge disposition and mortality did not differ significantly between groups (Supplementary Table 4). Although GCS improved significantly within each group from admission to discharge (all *p* < 0.001), intergroup differences were not significant (Supplementary Table 5). Discussion This randomized controlled trial demonstrated that propranolol, alone or with gabapentin, significantly reduced PSH incidence following moderate-to-severe TBI compared with standard care alone [14]. Propranolol effectively attenuated cardiovascular manifestations such as tachycardia and HTN [15], while adding gabapentin broadened symptomatic control across the PSH spectrum [16]. Secondary outcomes showed shorter MV, ICU stay, and hospital stay in the propranolol group, though these benefits were less consistent with combination therapy. Neurological recovery (GCS) improved significantly within all groups without intergroup differences, and mortality remained comparable. The three study groups were well balanced at baseline with no significant differences across demographic, clinical, radiological, or laboratory variables (Table 1). Trauma characteristics were evenly distributed, with RTA accounting for the majority of injuries and severe TBI predominating across all groups. Follow-up imaging showed a higher frequency of persistent brain edema in the control group compared with treatment groups, which may reflect a neuroprotective effect of propranolol and possibly gabapentin through modulation of sympathetic overdrive a process involving excitotoxicity, inflammation, and metabolic dysregulation linked to poor outcomes in severe TBI [6]. Taken together, this baseline homogeneity minimizes the potential for confounding and supports the validity of attributing subsequent differences in outcomes to the pharmacological interventions under investigation [17]. PSH is a well-recognized complication of severe TBI, associated with prolonged MV, extended ICU stay, and worse neurological recovery [18]. Our study focused on PSH incidence within this high-risk population, which aligns with reported rates of 8–33% (up to 50% in severe cohorts) [1, 2], differing from etiological prevalence reviews where TBI accounts for a smaller proportion of all PSH cases [19]. Beyond diagnostic challenges, PSH has important clinical implications: it is associated with prolonged MV, extended ICU and hospital stay, and, potentially, worse neurological recovery. Accordingly, strategies to prevent or attenuate PSH are a key priority in neurocritical care research [20]. Our findings demonstrate a clear reduction in PSH with β-adrenergic blockade. Compared with standard care (60%), propranolol reduced incidence to 33.3%, and the combination further lowered it to 10% (ARR 26.7–50%; NNT 2–4). The symptom pattern aligned with expected pharmacodynamics: propranolol attenuated tachycardia and HTN [21], while gabapentin broadened control to non-cardiovascular features [7]. The significant improvement in critical care outcomes with propranolol suggests a broader therapeutic benefit beyond discrete PSH episodes, supporting early intervention in high-risk patients [22]. The apparent paradox combination therapy achieving the lowest PSH incidence yet propranolol monotherapy showing the shortest MV, ICU, and hospital stays deserves consideration. Propranolol’s superiority likely stems from targeted mitigation of catecholamine toxicity without gabapentin’s sedative burden [22]. Cardiovascular symptom control may be sufficient to accelerate recovery, while combination therapy may be reserved for refractory cases [12]. Possible explanations include gabapentin’s sedative profile modestly slowing wakefulness and extubation readiness, multifactorial determinants of length-of-stay diluting the impact of PSH prevention, and sample size limitations reducing precision around secondary endpoints. These hypotheses warrant further targeted studies [23]. Our results are broadly consistent with prior work. β-blocker use has been associated with reduced autonomic storm burden and improved outcomes [16, 24], with propranolol serving as first-line therapy in protocolized pathways [25]. Conversely, not all series demonstrate uniform benefit on length-of-stay or ventilator duration, underscoring that PSH is only one determinant of critical-care course [26]. Evidence for gabapentin remains adjunctive [27]. Our randomized data add two signals: (1) propranolol effectively prevents PSH with strong cardiovascular control, and (2) early combination maximizes PSH prevention without superior resource utilization. Clinically, these findings support early propranolol after ICU admission with vigilant monitoring, adding gabapentin when broader PSH features emerge [15, 28]. Safety outcomes showed no excess hemodynamic risk with propranolol [29], and sedation practices were balanced across groups, though the combination group showed a trend toward higher propofol use [30, 31]. The divergence between PSH incidence and resource utilization propranolol monotherapy achieving shorter ICU stay (9.6 vs. 19.5 days) despite higher PSH incidence than combination therapy underscores the multifactorial nature of ICU outcomes [18, 32]. Propranolol may confer a more favorable balance by targeting cardiovascular surges without additional sedation [18]. These findings resonate with observational cohorts linking β-blockers to shorter ICU stay and improved survival [32, 33], though randomized data remain limited: a pilot RCT by Cruickshank et al. suggested propranolol reduced sympathetic surges and ICU instability, but sample size constraints precluded definitive conclusions regarding length-of-stay [34]. Gabapentin’s sedative profile may partly offset gains in extubation readiness. Case series (e.g., Baguley et al.) describe benefit in controlling paroxysmal sympathetic storms and neuropathic features [35], but no study has demonstrated consistent reductions in MV duration or ICU length-of-stay [20, 25]. Overall, propranolol reduced PSH and translated this into shorter MV, ICU stay, and hospitalization [36]. Combination therapy, while achieving lowest PSH incidence, did not confer parallel ICU efficiency gains [18, 20]. Propranolol emerges as the most pragmatic intervention, with combination therapy reserved for refractory cases [32]. Discharge outcomes showed favorable trends without statistical significance [36–38]. Neurological recovery (GCS) improved significantly within each group, but intergroup differences were not significant [39, 40], aligning with literature where β-blockers consistently reduce acute complications but direct neurological improvement remains less definitive [41, 42]. Limitations Several limitations should be acknowledged. First, the single-center design and moderate sample size (n = 90) may limit generalizability. Second, unmasking due to drug side effects remains possible despite blinded assessment. Third, follow-up was restricted to acute hospitalization, precluding long-term functional assessment. Fourth, competing mortality complicates LOS interpretation. Fifth, the large treatment effects (54–51% reductions) are biologically plausible but require replication. Finally, findings are specific to gabapentin-naïve patients; applicability to other populations remains unexplored. Future work Future research should prioritize multicenter trials for validation, dose-optimization studies, comparative effectiveness against other sympatholytics, biomarker development for precise phenotyping, and exploration of gabapentin’s immunomodulatory properties. Conclusion This trial demonstrates that early propranolol significantly reduces PSH incidence and improves critical care outcomes in moderate-to-severe TBI. While the combination showed superior PSH prevention, it conferred no added benefit for resource utilization. Propranolol represents a promising prophylactic strategy, with gabapentin reserved for refractory cases. Replication in larger trials is needed before definitive recommendations. Supplementary Information Supplementary Material 1. Acknowledgements The support of the neurosurgical ward, operating room, and surgical ICU at Zagazig University Hospital in providing the essential data for the conduct of this study is gratefully acknowledged. Abbreviations Acute kidney injury Analysis of variance Beta blocker Body mass index Confidence interval Consolidated Standards of Reporting Trials Chronic obstructive pulmonary disease C-reactive protein Computed tomography Central venous line Diffuse axonal injury Diastolic blood pressure Disturbed conscious level Diabetes mellitus Epidural hematoma Falling from height Gamma-aminobutyric acid Glasgow coma scale Hemoglobin Hepatitis C virus Heart rate Highly significant Honestly significant difference Hypertension Intracranial pressure Intensive care unit Intention-to-Treat Internal jugular vein International normalized ratio Interquartile range Institutional review board Length of stay Least significant difference Mean arterial pressure Mechanical ventilation Nasogastric tube Non-significant Oral hypoglycemic drug Pelvic-abdominal ultrasound Per os (orally) Paroxysmal sympathetic hyperactivity Partial thromboplastin time Respiratory distress Respiratory rate Road traffic accident Significant Subarachnoid hemorrhage Systolic blood pressure Standard deviation Subdural hemorrhage Traumatic brain injury Ventilator-associated pneumonia Authors’ contributions E.M.N., M.E.M.K., and A.M.G. conceptualized and designed the study. E.M.N., M.E.M.K., H.M.F., and O.M.F. were responsible for organizing the database. E.M.N. and M.E.M.K. conducted the statistical analysis, while E.M.N. and H.M.F. prepared the figures and tables. The initial draft of the manuscript was written by M.E.M.K., E.M.N., and A.A.F.E., with contributions to specific sections by E.M.E.Y. and O.M.F. A.A.F.E. and E.M.E.Y. contributed to data collection and clinical insights. E.M.N. and A.M.G. contributed to data interpretation and manuscript formatting. All authors participated in manuscript revision, provided critical feedback, and approved the final submitted version. Funding Open access funding provided by The Science, Technology & Innovation Funding Authority (STDF) in cooperation with The Egyptian Knowledge Bank (EKB). There are no specific financial interests, relationships, or affiliations relevant to the subjects of the manuscript. Data availability The datasets generated and analyzed during the current study are not publicly available but are available from the corresponding author upon a reasonable request. Declarations Ethics approval and consent to participate This study was conducted in accordance with the principles of the Declaration of Helsinki. Ethical approval was obtained from the IRB of Zagazig University (IRB No. 9076/8-11-2021). Informed consent was obtained from all patient’s legal representatives prior to their inclusion in the study. Consent for publication Not applicable. Competing interests The authors declare no competing interests. Footnotes Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Essamedin M. Negm and Ahmed M. Gouda contributed equally to this work and share first authorship. References Associated Data Supplementary Materials Supplementary Material 1. Data Availability Statement The datasets generated and analyzed during the current study are not publicly available but are available from the corresponding author upon a reasonable request.